JP2024517477A5 - - Google Patents
Info
- Publication number
- JP2024517477A5 JP2024517477A5 JP2023569861A JP2023569861A JP2024517477A5 JP 2024517477 A5 JP2024517477 A5 JP 2024517477A5 JP 2023569861 A JP2023569861 A JP 2023569861A JP 2023569861 A JP2023569861 A JP 2023569861A JP 2024517477 A5 JP2024517477 A5 JP 2024517477A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- composition
- patient
- use according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187903P | 2021-05-12 | 2021-05-12 | |
| US63/187,903 | 2021-05-12 | ||
| US202163231384P | 2021-08-10 | 2021-08-10 | |
| US63/231,384 | 2021-08-10 | ||
| US202263313570P | 2022-02-24 | 2022-02-24 | |
| US63/313,570 | 2022-02-24 | ||
| PCT/US2022/028456 WO2022240799A1 (en) | 2021-05-12 | 2022-05-10 | Ripretinib for treating melanoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517477A JP2024517477A (ja) | 2024-04-22 |
| JP2024517477A5 true JP2024517477A5 (OSRAM) | 2025-05-20 |
Family
ID=81854549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569861A Pending JP2024517477A (ja) | 2021-05-12 | 2022-05-10 | 黒色腫を治療するためのリプレチニブ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240122906A1 (OSRAM) |
| EP (1) | EP4337201A1 (OSRAM) |
| JP (1) | JP2024517477A (OSRAM) |
| AU (1) | AU2022273288A1 (OSRAM) |
| CA (1) | CA3218436A1 (OSRAM) |
| WO (1) | WO2022240799A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746059B1 (en) | 2018-01-31 | 2026-03-04 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3746059B1 (en) * | 2018-01-31 | 2026-03-04 | Deciphera Pharmaceuticals, LLC | Combination therapy for the treatment of gastrointestinal stromal tumors |
| TWI878335B (zh) * | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
-
2022
- 2022-05-10 AU AU2022273288A patent/AU2022273288A1/en active Pending
- 2022-05-10 JP JP2023569861A patent/JP2024517477A/ja active Pending
- 2022-05-10 CA CA3218436A patent/CA3218436A1/en active Pending
- 2022-05-10 WO PCT/US2022/028456 patent/WO2022240799A1/en not_active Ceased
- 2022-05-10 EP EP22726903.2A patent/EP4337201A1/en active Pending
-
2023
- 2023-11-09 US US18/505,396 patent/US20240122906A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025176093A5 (OSRAM) | ||
| JP2022544234A5 (OSRAM) | ||
| JP2021113201A5 (OSRAM) | ||
| JP2024514202A (ja) | Ｅｒｋ１／２の複素環式阻害剤の使用 | |
| TWI878335B (zh) | 治療胃腸道基質瘤方法 | |
| US20240423978A1 (en) | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | |
| EP4110326A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| JP2022526159A5 (OSRAM) | ||
| JP2022502492A5 (OSRAM) | ||
| CN115006397A (zh) | 一种预防或治疗肿瘤疾病的药物用途 | |
| WO2020114348A1 (en) | Methods for cancer therapy | |
| EP4093394A1 (en) | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | |
| JPWO2005009444A1 (ja) | 医薬組成物 | |
| WO2024023766A1 (en) | P13k inhibitor combination therapy | |
| WO2019220375A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| WO2022234409A1 (en) | Compounds and compositions for the treatment of mpnst | |
| WO2021094379A1 (en) | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer | |
| JP2005526821A (ja) | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
| Zachariah et al. | Antihypertensive effects of a new sustained‐release formulation of nifedipine | |
| CA3255389A1 (en) | Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Combination with an AKT Inhibitor for the Treatment of Cancer | |
| WO2025248485A1 (en) | Pharmaceutical compositions and methods of use thereof | |
| TW202304457A (zh) | 配製物 | |
| JP2025540124A (ja) | 乳がんを治療する方法 | |
| HK40030002B (zh) | 癌症疗法 |